2009 Jan. 15, ecnp matters NEWSLETTER NO.

Report from the Scientific Klaus-Peter Lesch st Winner ECNP Award Programme Committee 21 ECNP Page 2 Congress, 30 August - 3 September New initiative 2008, Barcelona, Spain ECNP School of ­Neuropsychopharmacology Sven Ove Ögren, Sweden, chair Page 2 It is a great pleasure to give my impression as a number of European scientists and the chair of the Scientific Programme Committee intensive evaluations of the proposals per- (SPC) to the 21st ECNP Congress in formed by members of the SPC. I hope that Next ECNP Congress Barcelona. As in the last two years, the con- this creative interaction between ECNP and Istanbul 2009 gress attracted a large number of delegates individual scientists can be further developed Pages 1, 3 and 4 (close to 7400) who filled the lecture rooms to make the ECNP Congresses outstanding from morning to late afternoons throughout events. In addition, there are now well devel- the congress. I was delighted to notice that oped avenues by which ECNP members Interview the three plenary lectures attracted such a and the ECNP Scientific Advisory Panels Jacques Glowinski large audience. It was satisfying to see that (SAP) contribute to the final programme Since 2006, ECNP organises Targeted symposium recent scientific achievements Page 4 the number of people wishing to attend a by organising the brainstorming sessions Expert Meetings (TEMs) ) to promote the have been presented. The lectures in the particular symposium was overall very high. and proposing the ECNP Targeted Expert exchange of ideas between members of the clinical Breaking News symposium were In addition, the audience has been very Meeting symposia, respectively. ECNP Scientific Advisory Panels (SAP), of high level, but there is a need for more active. I was particularly impressed by the experts, and European scientists between translational approaches. 21st ECNP Congress lively discussions and strong involvement Barcelona has further reinforced the tradi- 5-15 years post-doc. Four meetings are held 30 august – 3 September 2008 of the delegates. The lay-out of the congress tion within ECNP of blending innovative just before the ECNP Congress and partici- Summing up, the ECNP Congress in venue allowed the participants to encounter science with novel clinical applications and pation is by invitation only. The TEMs have Barcelona was undoubtedly a great success TEM symposia each other frequently thereby creating addi- therapeutic inventions. This development become very successful and we are grateful measured by any criteria. I am convinced tional possibilities for interactions. is reflected in the number of new initiatives for the input from all the participants and that everyone attending the congress feels S.05: Cognitive impairment in taken by ECNP during the last few years. the additional work done by the coordina- that he or she has learned many new interest- ­affective disorders: a potential The major aim of the SPC is to create a ECNP has taken the initiative to inspire tors. One of the output requirements for the ing things which captivated one’s scientific treatment target? high quality scientific programme with a and motivate young scientists in high qual- TEMs is to submit a symposium proposal imagination. I think that the 21st ECNP balanced mix between basic/clinical science ity research by special symposia called the for the next ECNP Congress. In Barcelona Congress gave all of us the lasting feeling S.11: Preclinical and translational and applied clinical developments. Another Hot Topics symposia. Selected presenta- four symposia have been submitted by the that there is a great future for neuropsychop- research in improving clinical ­outcomes in anxiety disorders important aim is to report on new and excit- tions from the annual ECNP Workshop TEMs from 2007. I am looking forward to harmacology in Europe. ing discoveries in the field of neuropsychop- in Nice in the Hot Topics symposia gave the contribution of the TEMs 2008 for the S.16: Neurogenesis and stem cell harmacology. I think that the 21st ECNP a good impression of the high quality of 22nd ECNP Congress in Istanbul. Finally, I would like to express once more my Congress, in an excellent manner, managed young scientists within Europe. I think thanks to all contributors, and in particular S.19: Translational issues in ­dementia to fulfil both these aims. This achievement everybody visiting these symposia was Our knowledge of brain mechanisms of the ECNP-Office, who made the 21st ECNP depends to a large extent on the input from impressed by the quality and variety of the relevance for health and disease is rapidly Congress such an overall success. many sources, i.e. symposium proposals, from presentations. increasing. In the preclinical Breaking News

22nd ECNP Congress: Submission Highlights ECNP Workshop on of papers is open Neuropsychopharmacology for The Scientific Programme Committee invites delegates who intend to present a Young Scientists in Europe 2009 poster to submit the corresponding paper. Eduard Vieta, Spain chair ECNP Workshop Committee The paper will be reviewed for presentation and publication. A paper that is not pub- As the new chair of the ECNP Workshop sions and are required to present a poster at lished can still be accepted for presentation. Committee, it is my pleasure to write a few one of the two poster sessions. During these words on the upcoming workshop to be held poster sessions there will be ample time to The deadline for submission is 31 March from 5-8 March 2009 in Nice, France. interact with the senior scientists. 2009. This year we will have as a fourth topic An additional stimulant for the selected For instructions on preparation of papers ‘Addiction: towards new drug targets’. For participants to prepare a high level poster and further information please visit the this session, we are very honoured that is the possibility to be selected by the ECNP website www.ecnp.eu. George Koob and Barbara Mason from the Workshop Committee for a presentation at Department of at the the 22nd ECNP Congress, 12 - 16 September Scripps Research Institute, La Jolla, USA 2009, Istanbul, Turkey. I can assure you this have accepted the invitation to share their opportunity is quite a challenge for both the vast experience in the field with the young poster presenters and the scientific commit- scientists in Europe. tee involved!

All 90-100 invited young scientists are expected For further details on the programme to be present throughout the entire workshop, you are invited to visit the ECNP website ­ as they play an active role during the discus- www.ecnp.eu. Call for symposia proposals for the 23rd ECNP Congress, 28 August - 1 September 2010, Amsterdam, The Netherlands

The Scientific Programme Committee (SPC) by the SPC please visit the ECNP website is inviting you to submit a symposium pro- www.ecnp.eu. posal for the 23rd ECNP Congress. The deadline for submission is 31 March For details on the requirements for the 2009. proposal and the selection criteria handled

1 Interview with the winner of the 2008 ECNP Neuropsychopharmacology Award in Clinical Research: Klaus-Peter Lesch, Germany

How does it feel to be one of the authors small effects, and an important question is of what appeared to be a ‘key’ paper in how these small effects interact to lead to the research for personality traits that a phenotype. On the other hand, there is editor influence mental diseases and their treat- as yet no concept to answer the question ment? How did this influence you and whether genetic testing for genes involved your work? in a complex trait or behavioural disorders is predictive for moderating events across the The discovery of serotonin transporter gene entire lifespan such as developmental and variation and its role in personality dimen- adult neuroplasticity. Although the inter- sions itself was a small first step; however, it individual variability is huge and many dif- resulted in extensive follow-up research by ferent aspects are involved at a genetic level, our group and independent investigators on the ultimate goal is to find the molecular Maria Vrijmoed Maria – Vrijmoed de Vries The Netherlands, interview different perspectives such as anxiety, stress basis that regulates behaviour. Here, we tear effects and neuroimaging. It also opened down the myth about the uniqueness of new avenues of research, such as the impli- human behaviour but we also believe that cations for the ‘social brain’. There has been individuals are unique in a fundamental way. an educational update session on the societal This contrast makes the work for basic and implications of chaired by me clinical scientists extremely difficult. at the 21st ECNP Congress in Barcelona. How do you look at the perceived lack of The work on serotonin transporter gene efficacy of antidepressants as reported in variation as a ‘model’ system in neurobi- the press? ology has been remarkably broad. Sixty years after the discovery of serotonin and I think this form of reporting by the 21st ECNP Congress 40 years of research on the binding site of press is primarily doing a disservice to the 30 August – 3 September 2008 serotonin reuptake inhibiting antidepres- patients by re-enforcing their confusion. sants, the focus is directed towards cloning Programme educational update The response of patients to antidepressants ­session E.06 genes and detecting gene variation as well is highly individual and also relates to the as understanding gene regulation. What personal relationship with the treating psy- Society and neuroscience: will be the next levels of complexity? In any chiatrist as well as other complementary the ­neuroethics conundrum case, we will require both basic and clinical components of therapy. Clinical trial situa- Moderator: Klaus-Peter Lesch, research approaches. We will have to proceed tions are often highly artificial and far away Germany toward an integration of molecular genetics from the therapeutic reality. Using common into the cellular biology of neuronal circuits sense in conducting and assessing clinical tri- Society and neuroscience: a European and neural systems function. Techniques like als, occasionally also using an open design in perspective psychophysiology and neuroimaging will a ‘real life’ situation in a single study centre, Nikolas Rose, United Kingdom help to establish intermediate phenotypes as well as sensible information of the patient in both healthy individuals and patients. Klaus-Peter Lesch was born in Würzburg, Germany. Currently, he is would in my opinion get us beyond the cur- Philosophical challenges in neuro­ Moreover, we will witness increasing research Professor of Psychiatry and Psychotherapy, Vice Chair and Director ADHD rent dilemma. ethics efforts focussed on genetically modified Programme, Molecular and Clinical Psychobiology, Department of Psychiatry, Kathinka Evers, Sweden mice. Finally, studies on gene-environment Psychosomatics and Psychotherapy, University of Würzburg, Germany. You are a trained psychiatrist and psy- interaction in humans and animal models, Klaus-Peter Lesch is married and has four children. chotherapist, are you (still) involved in Ethical issues of psychopharma­ including non-human primates and rodents, patient care? ceutical enhancement will reveal the mechanisms involved in the Thorsten Galert, Germany long-term outcome of emotion regulation Yes, I am. I am responsible for a ward of and cognitive function. I think this will lead The way you and your team combine of biology and psychology, whereas there is 21 inpatient beds. In general, two residents to a new view how we perceive neuropsy- results from so many different techniques currently a lack of young physicians ensuring are at work on this ward for the day-to-day chopharmacology and, eventually, how we into one complete (clinical) picture seem a direct link with the needs of the patients. patient care. I teach clinical psychiatry but perceive ourselves as humans. to be an example of ‘real’ neuropsycho­ It is difficult to get these young physicians consider the official classification system for pharmacology. Are the (young) research- interested in translational research, improv- psychiatric disorders too narrow and not Translational research is a hot issue nowa- ers working at your institute trained to ing this current unsatisfactory situation is founded in neurobiology; it creates many days: you seem to have been working at become true neuropsychopharmacolo- indeed one of my future goals. problems for teachers with a translational the forefront in this respect. What are gists? view regarding training on the job. your thoughts on this subject? What is your reaction to the quote in the My group conducts research in genetics, summary of the nomination: Would you like anything to add to the My groups’ research has indeed always been gene regulation, morphology of neurons and ‘5-HTT has become a model molecule above? going from the bedside to the bench and neuronal circuits, as well as neuroimaging. par excellence in cognitive, biosocial, and back. As a student I was interested in brain This group is truly ‘European’ with scien- psychiatric , clinical neu- ECNP is a very fine organisation. The sci- research from the beginning. This led me tist from different countries and scientific roscientists are faced with a new wealth entific quality of the ECNP Congresses has to explore the scope of neurology and neu- backgrounds with English as the working of genomic data and the potential for been increasing enormously over the years. rosurgery. But both fields did not meet the language. With respect to animal work, we manipulating genes, and the question I favour the low number of tracks and sym- expectations I had in linking behaviour to generate new models of genetically modified arises ‘What are the future challenges and posia very. Finally, the ECNP involvement brain function. I therefore switched to psy- mice and have established collaboration with limitations for determining the genetic in pertinent issues, such as ‘Society and chiatry and neuropsychopharmacology with a large number of national and international influence on behavioural traits?’ Neuroscience’, is critically important. a special focus on molecular neuroscience. In centres. With this collaborative effort we have that combination I was able to work at the a guaranteed flexibility of performance, and The future challenge certainly lies in the interface of basic and clinical research, with the training of ‘true’ neuropsychopharma- transformation of the flood of genetic data the aim to bridge the ever increasing gap cologists comes as a natural. The majority of into the cellular neurobiology at the func- For the report from the ECNP Award Jury between the two approaches. our groups’ researchers stem from the fields tional level. Individual genes exert very 2008 see page 3.

New initiative in 2009: The ECNP School of Neuropsychopharmacology

The Executive Committee has decided to start a new initiative for European clinicians: and optimal treatment and algorithms. the ECNP School of Neuropsychopharmacology, of which the first version will be held The school is envisaged to be an annual, 4-5 days residential course for young clinicians in July 2009, Oxford, United Kingdom. within 5 years of their qualifications, i.e. the potential future key leaders in neuropsy- chopharmacology in individual European countries. Participation to the school will be The aim of the school is to teach neuropsychopharmacology in all its aspects: from its on invitation only. Members of the ECNP Advisory Board of National Societies will be fundamentals to the use of medications in individual indications, good clinical practice invited to each recommend a maximum of two candidates.

2 (ENP) in the congress bag. bag. congress the in (ENP) the to supplement journal congress the of copy paper the include automatically longer no to decided has ECNP onward, 2009 From friendly environmental an taken has ECNP 22 the of papers published the that note Please of price www.ecnp.eu.website a ECNP the on available at it order 20 Euro still can to supplement ENP congress the of copy paper the in interested really are that Participants resources. natural of preservation the to contrib- ute to wants ECNP initiative, this By six weeks before the start of the congress. the of start the before weeks six website ECNP the on available be will Systemthat Information Congress the via and fee, registration the in included CD-Rom, h EN Flosi Aad a be etbihd o upr te tedne f excellent Congresses. ECNP at Europe in PhDs of and MDs years, 40 than attendance older not i.e. young, the support to established been has Award Fellowship ECNP The Award2009 Fellowship ECNP applications for Call 22 the for paper your You may indicate your interest in applying for the ECNP Travel Award 2009 while submitting Congress. ECNP the at participate to scientists ECNP the with Travelawarded be will young stimulate to Award.aims ECNP awardBy this young of papers best The Award2009 TravelECNP applications for Call Continued from page 2. page from Continued of relevant preclinical models in mice. Klaus-Peter Lesch and his group have been the first to (TPH2). 2 first hydroxylase tryptophan and the 5-HTT in deficient mice generatemutant been have group his and Lesch Klaus-Peter mice. in models preclinical relevant of development the on researchbased this is of aspect treatments.Animportant drug by targeted be neuropsychiatric disorders and have given indications of the final common pathways which could ings have increased our knowledge on the multiple mechanisms underlying altered of the pathophysiology of role the elucidated phenotypes. has variousfind- interactions in These interneuronal as well intraneuronalas signalling Lesch Klaus-Peter psychiatry clinical to genetics molecular from techniques anxiety,(MAOA)using Bydepression.in A and oxidaseaggression monoamine and (5-HTT) transporter 5-HT (5-HT1A), subtype 5-HT1A-receptor the of on neurobiology discoveries the important to led has work The cognition. and regulation emotion attention, of disordersin system (5-HT) brainserotonin the of role the is studies his in theme major A netics. with internationally recognised and - ogy pharmacoge contributions in neuropsychopharmacology neuropsychopharmacol- clinical and basic on focused researchKlaus-Peterbeen The of has Lesch distinctions. and awardsprestigious receivedseveral international has he and (ISI) Information Scientific for Institute the to according field the researchersin cited most the of one morepublished rankinghigh in them of most papers, original 260 than He journals. scientific is has Lesch of Klaus-Peter Department Würzburg. the of Psychotherapy, University at Professor and Psychosomatics appointed Psychiatry, was he 2000, In 1993. in psychiatry and therapy psycho - in certificate his and 1990-1992 USA Bethesda, (NIH), Health of Institute National the at fellowship a received He Würzburg. of University the at education postgraduate his and 1977-1981 during school Medical the undergraduatetrainingat receivedKlaus-Peterhis Lesch disorders.psychiatric of number a and disorders personality the serotonin transporter geneandhissubsequentdiscoveries ofthisfindingfor oftheimportance of promoter the on polymorphism a on researchinnovative Lesch’s Prof.and on pioneering sion Psychotherapydeci- Universityand Germany.of its the based at Würzburg, has jury award The Psychiatry of Professor Lesch, Klaus-Peter is awardee the and research, clinical in contributions recognises prize year’s This disciplines. related closely and distinguished neuropsychopharmacology recognisein research to established been has Award Neuropsychopharmacology ECNP The AwardECNP Jury chair SvenSwedenOveÖgren, 2008 AwardJury ECNP the from Report nd The deadline for submission of applications is applications of submission for deadline The www.ecnp.eu.website ECNP the visit please information Forfurther CP oges a b fud n the on found be can Congress ECNP Neuropsychopharmacology European through the online registration form form registration online the through

22 interview initiative ­initiative nd nd ECNP Congress. ECNP ECNP Congress, 12 - 16 September 2009, Istanbul, TurkeyIstanbul, 2009, September 16 - 12 Congress, ECNP cetss n uoe acpe fr ulcto ad presentation, and publication for accepted Europe, in scientists

The deadline for submission is submission for deadline The www.ecnp.euinformation. website further ECNP for the at site member the visit please If you are interested in one running of the brainstorming sessions at the 22 session at the 22 the at session brain­ a propose to members for Call 31 March 2009. March 31 31 March 2009. March 31 nd ECNP Congress ECNP one of the pre-eminent researchers in the field of neuropsychopharmacology.of field the researcherspre-eminentin the of one is Klaus-PeterLesch achievements, scientific creative and pioneering his of summary,Inbecause interactions.gene-environment to relates this how and behaviour human in complexity the of understanding deeper a up open will neuroscience, tive cogni- and genetics behavioural of integration on based psychopathology.research, to This relate they how and polymorphisms genetic 5-HTT by modulated pathways molecular and neuronal behaviour.human complex of modulation Klaus-Petercurrentlythe the investigatingis in Lesch including e.g. social interaction and emotion regulation showing a broad role of the 5-HTT-gene The above described research paradigm has recently been extended to complex human phenotypes genotype. S the carrying monkeys in reactivitystress and cognition regulation,social emotion for moredetrimental is development in period critical a ing primates and rodents. Importantly, Klaus-Peter Lesch and his group demonstrated that stress dur- humans, in both demonstrated been have interactions gene-environment important knowledge, importance of gene-environment interactions under strictly controlled social conditions. With this not only exist in man but also in non-human primates which allowed studies to directly assess the depression.In recent demonstratedwas L-relatedit and studies S similar the polymorphisms that to susceptibility and anxiety including traits personality several with associated is promoter gene variant.Subsequent(L) havedemonstrated5-HTT long studies the the of to polymorphism that compared 5-HTT of expressiondifferent a in resulted gene the of variant promoter (S) short the at the promoter5-HTT which results inter alia in variations in 5-HT neurotransmission. Thus, polymorphism the of consequences functional the demonstrated group his and Klaus-PeterLesch 5-HTT.encodes which gene the of promoter the in polymorphism In several papers fundamental a with traits anxiety-related between association an of discovery the to relates Science,1996) in (published finding important particularly A disorders. psychiatric various and drugs chotropic psy- to response traits, personality with associated polymorphisms gene of role the on discoveries pioneering to led group his Murphyand receptorsite. Dennis collaboration this with The on act serotoninantidepressant most since reuptake particular in and drugs sant drugs (SSRI’s)blockers knownis haveto antidepresroleof 5-HTT critical action cleft. a of synaptic mechanisms the in - the from transmitter the removes it since synapse the at transmission 5-HT fine-tunes 5-HTT 1990’s. early the in regulation emotional in 5-HTT of role the examine to started Lesch Klaus-Peter NIH, the from co-workers his and Murphy Dennis TogetherDr with ypsa rm h 22 the from symposia the latter symposia rename to Young to Scientists Award decided been has it distinction, clear a make To symposia. Topics Hot the and symposia these between difference the understanding in difficulties participants encountered congress that noted been has the 22 the Youngat Awardsymposia Scientists ypsa t h 18 the at symposia Since the introduction of the Breaking News change name present: The 15 the At Hot Topicshistory: The symposia standard. high same, scientifically the of remain will content the ever, changed been Younginto AwardhowScientists - symposia; has Congresses ECNP the for symposia Topics Hot the of name The ProgrammeCommittee Scientific chair SvenSwedenOveÖgren, changed! has name the only assured: rest But onward. has been organised at the symposium 16 Topics Hot successful Another were press’.the from ‘hot topics present to invited institutes European renowned from neuroscientists preclinical promising young symposium Topicswhere track preclinical Hot the in organised was a time first the at the subsequent ECNP Congress. ECNP subsequent the at ers to participate in two Hot Topics symposia grounds, on the basis of their presented post- back- neuropsychopharmacology clinical and neuroscience basic from both scientists, young 16 select to evolved development the there, From www.ecnp.eu. website ECNP For the visit please meeting established. this on details more was Europe in Scientists Young for Neuropsychopharmacology Workshop on ECNP the latter, the on Based activity.ECNP the their in part taking in interest showing scientists young of number the also presentationsbut the itself of quality the been only not has success The 2003. in th CP oges n 02 for 2002, in Congress ECNP nd ECNP Congress ECNP th CP oges it Congress, ECNP nd nd storming th CP Congress ECNP ECNP Congress, ECNP Congress posia sym- Award Scientists Youngfuture: The f erpyhpamclg. o te 22 the For neuropsychopharmacology. of areas many the of one in involved Europe in ECNP continues to focus on young scientists hours 16.05 – 14.00 2009 September 13 Sunday neuropsychopharmacology interface on YoungAwardScientists symposium hours 11.05 – 09.00 2009 September 13 Sunday neuropsychopharmacologypreclinical on YoungAwardScientists symposium diary: your in them plan can you so programme, the in allocated already are they however, moment; this at available not are symposia the of details the Consequently Scientists Workshop Youngin Europe, 5-8 March, 2009 for Nice, France. Neuropsychopharmacology the on at place takes tion selec- opportunity The results. research the their present given to be will Europe in scientists young 16 Turkey, again 2009, Istanbul, September 12-16 Congress, ECNP

ecnp

nd 3 matters Interview with the winner of the 2008 ECNP Lifetime Achievement Award: Jacques Glowinski, France

If you would look back at the past 40 years When Mitterrand was elected as president of your involvement in brain research, of France, he introduced many changes what do you consider for yourself the for France and also expected the Collège editor most interesting discovery/research? de France to change. Because during my It was in 1959, while writing up a review time as member of the Collège de France, article on the inhibitors of monoamine I frequently addressed the need for renova- oxidase, that I had taken the decision to tion not only of the building but also of the devote myself to research in a new domain: institution Collège de France itself, I seemed neuropharmacology. I had discovered the to be the likely choice for president of the remarkable work of and of his Collège de France at that time. collaborators on the metabolism of tritiated noradrenaline in peripheral tissues, as well as Next to a thorough renovation of the build- Maria Vrijmoed Maria – Vrijmoed de Vries The Netherlands, interview Arvid Carlsson’s and his colleagues’ first arti- ings owned by the Collège de France, my cle that demonstrated that large quantities of ideas were to have one third of the chairs were present in the striatum and occupied by foreigners, 40 chairs to be consequently suggested that this precursor installed for a year, to select young(er) of noradrenaline was very likely a chemi- persons, initiate a journal, install an interna- cal mediator of the central nervous system. tional evaluation board, install cooperation The idea came to me of synthesizing radio- with the industry, and increase the P&R of active dopamine from Tyrosine-C14, and the Collège de France to make it even more developing a technique to inject the isotope open to the public. directly into the cerebral ventricles to bypass the blood-brain barrier and thereby directly Another aspect that lies close to my heart deliver dopamine-C14 into the brain. I was is the following. When the head of an hoping the radioactive amine would be INSERM Unit retires, the Unit is closed. I taken up by midbrain dopaminergic neu- think it should be possible for the good peo- rons and consequently facilitate the study of ple to apply for a stay of four years to estab- its metabolism and modulation by certain lish their own group, with the possibility of psychoactive substances. The first results From left to right: David Nutt, Jacques Glowinski and Sven Ove Ögren an extension for another four years. of this study were published in 1962 in the “Comptes Rendus de l’Académie des All of this is of course not an over-one-night Sciences”. A year later, in the same journal, Jacques Glowinski was born in Paris, France on 30 August 1936. process. A lot of the initiatives are still under I published my first results on the cerebral Currently he is active in overseeing the finalisation of the renovation of the construction, most of them now headed by metabolism of the newly available tritiated buildings of the Collège de France and in a jury for the governmental plans my successor. I am still involved in the reno- noradrenaline. for promoting scientific areas in 10 major cities in France. vation of the buildings. The subsequent most important aspects for Jacques Glowinski is married and has one child. me have been my contributions in the sixties Are you still active in the scientific arena? and seventies to the development of insight No, that book is closed. I retired in 2006. in and identification of the metabolism of teach new areas of knowledge and to favour ematician may thus succeed an historian or However, as a follow-up on my vast scientific the catecholamines (CA) and the identifica- interdisciplinary exchanges. a linguist an economist. No university rank and Collège de France experience, I have tion of the location of the CA neurons in the The Collège de France is organised by 52 is required of the person who is put forward; been asked by the government to participate rat brain. In particular the identification of chairs, ten of which are currently held by all that count is the importance and original- in a jury of 7 members to evaluate the gov- the mesocortical-prefrontal cortex neurons foreign professors, covering the whole range ity of his or her work. Thus, the Collège de ernmental programmes to develop scientific has had a large impact on our understanding of disciplines: mathematics, physics, chemis- France enjoys not only considerable freedom areas, i.e. university campuses, in the urban of CA related disorders of the brain such try, biology, history, archaeology, literature, in its teaching and research activities but can area of 10 major cities in France. Quite a as Parkinson’s disease and . linguistics, orientalism, philosophy, social adapt to the progress achieved in all fields of challenge, I can tell you! Follow-up research has been focussing on the sciences, etc. These are not permanent: the knowledge. significance of presynaptic receptors, plastic- possibility of changing the fields of the The requirement for teaching is not large, 20 ity of the CA system, glial cells, both astro- chairs allows for innovation. In addition to hours a year to be divided equally over col- How does it feel to be awarded with the cytes and microglia, and of GAP junctions. the 52 chairs mentioned above the Collège loquiums and seminars, part of which may ECNP Lifetime Achievement Award? de France also has four one-year revolving be given abroad. The teaching programme I feel vey honoured to receive this interna- chairs, two of which are reserved for foreign- changes every year and is open for free for tional prize. I would like to refer to all the You have played an important role in the ers. The president of the Collège de France all students. The number of participants others with whom I have worked all these Collège de France. What exactly does this is elected by the Assembly of Professors for per year mounts up to 100.000, whereas via years. I see the prize as recognition for all institution stand for? a period of three years, that can be extended internet another two million visit the pub- of us. Collège de France is a special institute not by another three years. lished recordings of the teaching activities. related to any university. It was established A member of the Collège has to retire at the Thank you ECNP! in the 16th century to serve as counterbalance age of 70. At the Assembly of the Professors, to the very strict university of the Sorbonne. the decision is made as to whether the title What has been your special goal as presi- For the report from the ECNP Award Jury Its initial goal was – and still is – to promote of a chair that has fallen vacant can be main- dent, i.e, l’Administrateur du Collège de 2008 see page 5. learning at the cutting edge of research, to tained or – most often – changed: a math- France?

exciting new data will be made available Breaking News symposia at the via the ECNP website www.ecnp.eu from 22nd ECNP Congress: a few changes 1 June – 15 July 2009. The timeslots of the Breaking News sym- Sven Ove Ögren, Sweden posia are already scheduled: Monday morn- chair Scientific Programme Committee ing and afternoon, 14 September 2009, Istanbul, Turkey. The Scientific Programme Committee – to hand out the programme and the (SPC) is very pleased with the constant selected Breaking News papers at the number of applications for a lecture in the registration desk Breaking News symposia at the last ECNP – to publish the selected Breaking News Congresses. papers on the Congress Information System (CIS) However, the communication on the selected lectures to the congress participants has Obviously the selected speakers will be asked proven to be a challenge. The SPC intends for permission to publish their Breaking to increase the awareness of the congress News papers on CIS. participants for the Breaking News symposia by implementing the following changes: Please note: the possibility to submit your

4 The topic of the meeting is: ‘Biomarkers and France. Nice, in March -10 8 for scheduled is Meeting Consultation ECNP 2009 The Meeting. Consultation ECNP into changed been has MeetingConsensus ECNP the of name The Meeting Consultation ECNP name: New www. website ECNP the visit please bers TowebsiteECNP the access mem- for pages connection. secure a via Visacard) or (Eurocard card credit by fee membership the pay to possibility the offer also now bers The renewed ECNP website pages for mem- Continued from page 4. page from Continued membership fee ­membership New: development of Collège de France.de Collège of development the to contributions important and lasting made has GlowinskiFinally, Jacques field. the in positions influential have today who neuropharmacologists first-class generationof whole a fostered He 1960’s. mid the in NIMH from returned he when neuropharmacology’, of role as a leader and a role model for generations of scientists. He established a ‘French school key a played has Glowinski Jacques achievements, scientific outstanding many his Besides neurotoxicity.to related mechanisms in (astrocytes) cell glial of role and their receptors in striatal function. The group also made significant contributions to the P/tachykinins substance of role the on emphasis with ganglia basal the in neuropeptides of the striatal DA system. Later Jacques Glowinski and his group established the important role of major importance for the DA hypothesis of schizophrenia, which until then was focused on discoverearlycharacterisethe and 1970’s.neuronsin DA cortical course, of is, finding This to first the was group his techniques biochemical of use Byneurons.the DA afflicting events neurodegenerative the of progression underlying mechanisms neuronal DA for implications important have neurons. studies DA These nigro-neostriatal of lesioning partial after nisms mecha- compensatory of role the and matrix) versus (striasomes compartments striatal the especially system, DA nigrostriatal the on focused studies Later brain. whole the on based regional differences of in CA turnover. demonstrationThese studies were at a time when most performed findings were allowing methods, analytical improved and method dissection brain novel a outlined therebyHe drugs. of class this of action of site the of understanding the for foundation the laying noradrenaline,thus of uptake inhibit antidepressants tricyclic that showed He approach. pioneering another intraventricularly:noradrenaline and (DA) Jacques Glowinski, mostly together with Iversen and Axelrod, injected radioactive dopamine catecholamine (CA) metabolism, notably by the use of carbon 14-labeled amines. At NIMH PubMed.in Several earlythe of (1960’s) brainstudying in technologies new established papers publications 650 to close by documented research pioneering this out carried During has years. he 40 period than more over spanning career research a has Glowinski Jacques ‘Administrator’its became and France2000. 1991 de in in Collège at Neuropharmacology.of Chair He appointed was Vice-PresidentProfessorialthe of Assembly and Professor as France de Collège joined Glowinski Jacques 1982 In Unit. INSERM of an Director 1974 in and INSERM, A. at ProfessorRecherche de chair Maitre became its he under 1969 In Neurophysiology Fessard. General of part a as France, de Collège at Neuropharmacology Biochemical group created newly the for director became he 1966 in and 1965, in France to From returned Glowinski Jacques USA. Bethesda, 1968. in NIMH at in postdoctoralstudies for 1963 Sciences in left Naturaland Pasteur Institut in the with associated graduated was he and 1961-1962 1960 in Paris and in Pharmacology of Pharmaceutics Institute the at diploma university his received Glowinski Jacques scientists. generationsinspiredof has which Europeanneuropsychopharmacology,in leadership outstanding his and brainmonoamines, of function and neurochemistry the on research pioneering his recognised has Jury Award instance Professor Glowinski is Commander of the National Legion d’Honneur. The ECNP research institutions in the world. He has numerous national and international honours, for prestigiousmost France,the de of President,AdministrateurCollège one as i.e. du served he 2000-2006 During positions. high at administrator an as and teacher a as scientist, a as Glowinski, ProfessorJacques at Collège de is France, Paris.year Professor Glowinskithis has Awarda long and Achievementdistinguished career Lifetime ECNP the of recipient The level. international and/or national a on who has made innovative and lasting contributions to the area of neuropsychopharmacology of Neuropsychopharmacology and is presented biannually in the recognition of an individual Europeanthe College by AchievementLifetime2005 Award ECNP in The established was AwardECNP Jury chair SvenSwedenOveÖgren, 2008 AwardJury ECNP the from Report

Online payment ECNP payment Online interview website www.ecnp.eu.website ECNP the on available are form registration online the and programme provisional The neuropsychopharmacology’.in treatments new developing in medicine experimental payment. online the make to possibility the including fee membership open your of left the hand side menu and you will see on an overview payment’ ‘online select Please password. and username personal your with in log and pages’,‘to member click ecnp.eu, The ECNP Targeted Expert Meetings Meetings Expert 2008 (TEM) held just before Targeted the 21 ECNP The ProgrammeCommittee Scientific chair SvenSwedenOveÖgren, and Camilla Haw,Camilla and UnitedKingdom. Switzerland, Anand, Ravi by discussed were data required. These is directives of nization harmo- a and Countries, Europeandifferent the in vary may antipsychotics of use label off- of management Regulatory drugs. these ble neurological and metabolic side-effects of possi- the to due impact clinical high a have as such populations childrenrequiresmay and attention higher a special in sychotics antip- of use Off-label approval. for regulatory required kind the of data by quality supported high not is antipsychotics of use off-label most that demonstrated Kingdom, In the first lecture, Guy M. Goodwin, United antipsychotics. with treatment of aspects clinical relevant several on focussed and W. Wolfgang Fleischhacker, Austria, was The meeting, chaired by Filippo Drago, Italy Italy,Drago,Filippo unique and knowledge a their enlarge to opportunity given the were which participants during invited programmes their for faculty excellent Panels, an attracting Advisory in succeeded Scientific ECNP the of members co-chairs, and coordinators The successful. very been have Congress Neurology Targeted2008 Report Meeting Expert Antipsychotics Disordersand Psychotic Targeted2008 Report Meeting Expert Spain Barcelona, 2008, August 30 - 29 Targeted2008 ECNP Meetings Expert is literature suggesting that the use of these of use the that suggesting literature is there antipsychotics, of ratio benefit-risk low the of Because countries. European some in only risperidone antipsychotics,presents a clinical indication generation second Among criterion. off-label an on based although mostly is common, it is PAD antipsychotics and of BPSD in use The (AD). Disease complicate the clinical evolution of may Alzheimer that situations pathological are (PAD) Disease Alzheimer of Psychosis and (BPSD) Dementia of Symptoms De Behavioural Psychological and Peter that showed lecture, Belgium, main Deyn, second the In ing traits, previous use of alcohol and illicit and alcohol of use previous traits, ing seek - novelty PD, of onset at age young to linked been has and syndrome’ regulation ‘dopaminedys- termed is PD in medication dopaminergic of use compulsive harmful, of syndrome This (‘punding’). behaviours tive repeti- stereotypic, and dyskinesias disabling of development the with associated is tion medica- dopaminergic of increase rapid The symptoms. motor their of for control adequate required those beyond far medication increasingtake which dopaminergic of doses However,patients PD of subgroup a is there usually addiction. are for risk low PD at being as 5 regarded with till Patients up ago. attention years little (PD) received disease which Parkinson’s of aspects psychi- atric certain on focussed meeting This WalterPirker, Austria, coordinator coordinator st ECNP aa ee icse b Jsf Marksteiner,Italy.Sacchetti, Emilio and Austria, Josef by discussed were Data functions. cognitive on drugs these of effects the on Moreover,demonstrated is benefit no risperidone. for specifically dementia, in sion aggres- and agitation dem- on efficacy available onstrating are data However, effects. adverse experience not do that patients those in justified only is PAD and BPSD in drugs efforts and enthusiasm. and efforts disordersantipsychotics)yourchotic and for W.and Drago Wolfgang (psy- Fleischhacker Filippo and (neurology) Corvol Christophe Jean- and Pirker Walter chopharmacology), neuropsy- adolescent & (child Arango Celso and Zuddas Alessandro (addiction), Brink Thank you Gabriele Fischer and Wim van den www.ecnp.eu‘Meetings’.under ticipants can be found on the ECNP website par- of lists and programmes The research. of field their in experts with issues discuss complications. these of management and improvediagnosis neurology, psychiatry and basic neuroscience research to between cooperation scientific and clinical close a for need a is there that and patients PD for caring challenge neurologists for major a represent disorders trol con- impulse and syndrome dysregulation dopamine the that demonstrated TEM The traits. seeking novelty and PD of onset at age young to linked also are but agonists dopamine taking patients PD in observed been have usually disorders ping and compulsive eating. Impulse control pathological as hypersexuality,gambling, such shop- pathological control impulse of disorders various to lead can PD in therapy replacement dopamine addition, In drugs. reports. lance pharmacovigi- and studies trials, marketing III post phase controlled by were both effects raised metabolic and death sudden ond generation antipsychotics. Furthermore, sec- and first between exists difference tial appears to be a class effect, where no substan- events adverse cerebro-vascular of incidence increased The France. Drici, Milou-Daniel and Netherlands, The Wied, Gispen-de C. Michael by Christine by discussed and Israel, Davidson, presented were issues Safety ecnp ­ 5 www.ecnp.eu‘Publications’ under website ECNP the on found be can meetings TEM from Reports matters

psychiatrists, and the extent of international Neuropsychopharmacology in collaborations, but also the original contri- Estonia butions made here. Small can be beautiful: there is just one Jaanus Harro, Estonia professorship in pharmacology and one in chair Local Advisory Committee 10th ECNP Regional Meeting psychiatry in Estonia, but several research groups pursue to a smaller or larger extent The University of Tartu (Dorpat) was chopharmacology in Estonia cannot claim a the research questions in common with founded in 1632 by Gustav II Adolf, King direct connection to these historical events. It neuropsychopharmacology or use neuropsy- of Sweden, and after its closure during may be worth considering, though, that the chopharmacological methods that have the armed conflicts between Sweden and historical atmosphere persisted as the psychi- emerged at several other departments of the Russia, reopened in 1802 by the Russian atric clinic of Kraepelin with a laboratory of University of Tartu. The most significant of Czar Alexander I. In the nineteenth century clinical psychopharmacology, his laborato- these are at the Departments of Chemistry, the language of instruction was German. ries at the Institute of Physiology, and most Physiology, and Psychology. Neurobiology This facilitated recruitment of young, highly notably the Department of Pharmacology of with relevance to neuropsychopharmacol- talented and motivated professors from Buchheim and Schmiedeberg were all still in ogy is now also emerging at the Tallinn Germany. Owing to this fact Tartu can their original use until the end of twentieth University of Technology and the University claim having been the cradle of experimental century. The author of this text has had the of Tallinn. Today psychopharmacologists pharmacology, as Rudolf Buchheim opened privilege to carry out psychopharmacological and addiction have been fostered. and the broader neuroscience community here his laboratory in 1847 and converted experiments in all of these places. in Estonia are studying depression, anxiety, materia medica, in which medicines were During the early period of the psychop- With Allikmets in the lead, the Estonian tra- eating disorders, and neurodegeneration at described in alphabetical order, into science harmacological revolution, the influential ditionally broad-based pharmacology went both clinical and animal modelling level. of pharmacokinetics and pharmacodynam- professor of psychiatry in Tartu, Jüri Saarma, for ‘psycho’: nowadays, all but one member Molecular genetic tools such as genetically ics based on principles of chemistry and clearly recognised how important the emerg- of the Estonian Society of Pharmacology are, modified animals, genome wide expression physiology. ing discipline of neuropsychopharmacol- or have been, active in neuropsychopharma- studies using RNA microarrays, genome ogy will become, and took the necessary cology. Estonian Psychiatric Association with wide association studies as well as candi- Buchheim’s successor, Oswald Schmiedeberg measures. However, it was only upon the its Biological Psychiatry Section is its large date gene approaches, the latter often with carried the Tartu tradition in 1872 to return of Lembit Allikmets from the labora- partner in sponsoring relevant research and focus on gene-environment interactions, Strasbourg. Parenthetically, Bernhard tory of Sergei Anichkov in St Petersburg in education. During the ‘reign’ of Allikmets have been added to the traditional instru- Naunyn, professor of internal medicine, made 1963 when the neuropsychopharmacologi- Estonian pharmacologists and psychiatrists ments. Bibliometric analysis as it can be a similar career decision at the same time, cal branch of research truly emerged. Lembit established the tradition of large, interna- done with present-days tools would suggest and in 1873 they together began to publish Allikmets first served as a researcher and sub- tional meetings every few years. While in that pharmacology is in some decline after what is now considered the first journal of sequently as head of a laboratory of experi- the 70ies and 80ies the international ties its height in the 90-ies when Estonia’s rank pharmacology and that presently bears their mental pathology and pharmacology, and were unstable and travel severely restricted internationally was very high. However, this names: Naunyn-Schmiedeberg's Archives of thereafter since 1972 as professor and chair- for obvious reasons, Tartu hosted the ‘All- is deceptive and largely caused by changes Pharmacology. While Schmiedeberg experi- man of the Department of Pharmacology. Union’ meetings that gathered hundreds of in publication strategies, with the majority mented extensively with several drugs act- He became the single founding father of scientists from all over the former Soviet of papers by contributors to neuropsycho­ ing on the central and peripheral nervous the Tartu school of psychopharmacology. It Union. The last in this series, in 1986, pharmacology now printed in journals rather system, most notably with muscarine, this was in his department and in the laboratory became too large for the remotely located classified into neuroscience or psychiatry. pioneering development in pharmacology of experimental and clinical psychophar- Tartu and took place in the Tallinn Olympic had no intentional neuropharmacological macology co-directed by the Departments Yachting Centre, a remainder of the Olympic We have highly valued the role of ECNP focus. But this was the area of keen interest of Pharmacology and Psychiatry, that all Regatta of the Moscow Games that had been in promoting neuropsychopharmacology. of Emil Kraepelin, who became professor of classes of psycho- and neuroactive drugs held in Tallinn. Truly international was the Estonia has been represented in the ­scientific psychiatry in 1886 and during his five years were studied. Besides behavioural, biochemi- 2nd Baltic Meeting on Pharmacology and program of the ECNP Congresses since in Tartu continued studies on effects of caf- cal and clinical investigations on antipsy- Clinical Pharmacology, in 1990. Tartu held 1992 (Marbella), and the psychiatrists of feine and ethyl alcohol on mental functions chotics, antidepressants, tranquillisers and somewhat smaller but high profile meetings the country have enthusiastically taken part that he had undertaken in the laboratory of antiparkinsonian substances, studies of more in 1995 and 2001. In 2006 Tallinn hosted in the ECNP Congresses. Seven young Wilhelm Wundt. fundamental nature such as on anxiety- a regional conference of CINP with 350 ­scientists of Estonia have received the ECNP producing drugs and neuropeptides, and participants. All this witnesses the network- Fellowship Award; this is as many as in the Two world wars later, modern neuropsy- psychopharmacology of aggressive behaviour ing ability of Estonian pharmacologists and United Kingdom or Israel.

As one of the founder members of European Brain Council (EBC), ECNP is proud to let you know European Commission and the pharmaceu- that her past-president, Julien Mendlewicz has been elected president of EBC. Below you will find tical industry should each fund five areas of his maiden introduction published in EBC’s latest newsletter health to the tune of €2 billion, one of which is the CNS. And last but by no means least, it has initiated a series of European Brain An update on the European Policy Fora, which will bring together all stakeholders in a major brain disease over Brain Council two days each year, to discuss the specific issues surrounding that disease. The first Julien Mendlewicz, Belgium, president Brain Councils (NBCs) based on the EBC such forum took place in February 2008 model now exist in five countries – Slovenia, and had Parkinson’s disease as its theme. The European Brain Council (EBC) came Belgium, Hungary, Norway and Italy – and The second, on depression, will take place in into being in March 2002 as a non-gov- National Action Groups (NAGs) are pro- Brussels on 25-26 February 2009. ernmental organisation that brings together moting brain research in nine others, while stakeholders in the field of brain research they explore their own potential for evolving Our goals for the future are to strengthen and brain diseases in Europe. Since then, it into NBCs. In this way, the EBC has begun our collaboration with our member organi- has succeeded in creating a dialogue between to build a pan-European network of organi- sations, in particular patients’ associations, as those different stakeholders – between basic sations, all of which share the same goals, well as with EU institutions, member states and clinical neuroscientists, between neu- and is building support from the bottom up and the World Health Organization, and to rologists, neurosurgeons and psychiatrists, as well as from the top down. It will continue promote research on the brain in health and between patients, carers and doctors, and to promote the establishment of NAGs and disease, in order to help improve the quality between industry and consumers – groups NBCs in the remaining European Union of life of patients. who have not always seen eye to eye. The (EU) states. proof that EBC has succeeded in achieving, in Europe*, the Consensus Document on Editorial note and perhaps more importantly, maintaining Top down pressure is important too, of European Brain Research, and Resource * commissioned by ECNP under the leader- that dialogue lies in the many projects it has course, and in order to impress policymak- Allocation to Brain Research in Europe. ship of Hans-Ulrich Wittchen, Germany, undertaken in the last six years. The credit ers in Brussels and in the national capitals, Further efforts are needed to collect reliable chairman of the ECNP Task Force. Results for these goes in large part to Jes Olesen, we must have data – notably health eco- data on all diseases of the central nervous on these studies have been published in who presided over the EBC Board from its nomic data, which show in black-and-white system (CNS), particularly in children, ado- a special issue of the journal European inception until this year, and to all those the scale of the problem Europe faces in lescents and the elderly. Neuropsychopharmacology Vol. 15(4),355- who served as its officers in that time. terms of brain disease, and the need for 490, 2005. An interview with Hans Ulrich more resources, information and training. Among the other important initiatives in Wittchen can be found in the newslet- Among the EBC’s greatest successes to date To that end, the EBC has commissioned which the EBC has participated is the ter ECNP Matters 9, October 2005 on has been the fact that it has provided a role and seen published three major studies: Innovative Medicines Initiative, which pro- the ECNP website www.ecnp.eu under model for European countries. National Size and Burden of Disorders of the Brain poses that over the next seven years, the ‘Publications’.

6 Other impressions from the 21 the fromimpressions Other 30 August - 3 September 2008, Barcelona, Spain Barcelona, 2008, September 3 - August 30 interview st ECNP Congress, ECNP improvement for suggestions and view of points Participants’ – – Suggestion: repetitive”.offered food during lunch time too long and the breaks the consider I but organised general, the ECNP Congress is well In dementia. vascular as such tias demen- other ignoredhave and tia dementia Alzheimer’sdemen- about all were about symposia “The CraigAustralia Wilson, kind”. and informed well are People ciency. effi- feel I organised. well very is congress the and favourable is very venue congress The disorder’. obsessive-compulsive in spectrums and -Endophenotypes ‘S.06 was most liked I that symposium The programmebalanced. wellaretific Congresses. The choices of the scien- “I have participated at many ECNP Italy Sergio Tomaselli Marzano, – Suggestion: science.” clinical and roscience neu- basic between gap large a felt I However, choose attend. to to one which difficult was It time. same the at symposia interesting many too were Thereexcellent. sia sympo- the of content the found “I Serbia Josifovic-Kostic,Dragana – – Suggestions: iouralneuroscience”. behav- and basic on focused more would be to Congresses ECNP the I expect aspects, important are behaviour and neuroscience basic neuropsychopharmacology within that Considering orientated. cal clini- too still the is Congress me ECNP for Nevertheless, 2005. in Amsterdam in Congress ECNP the to comparison in science, basic and clinical between balance ter bet- a offers congress Congress. the year This ECNP the at ticipate par- I that time second the is “It Carobrez,Brazil Antonio treatment, e.g. ECT e.g. treatment, physical about more offer to symposia the of slides or tape, audio video, to offer the possibility to buy a neuroscience to attract exhibitors from basic science neuro - basic from delegates of to participation the order stimulate in hospitals tutes, insti- research universities, in CongressesECNP promote to ecnp P.3.c.003 P.6.d.009 P.1.e.015 P.6.c.008 P.2.b.005 P.8.a.005 P.2.g.011 P.6.a.013 P.1.b.004 P.2.c.015 P.1.c.007 P.6.d.007 P.2.e.013 P.1.a.016 P.6.e.005 P.4.b.009 P.6.a.010 P.1.f.002 P.4.b.007 P.1.c.027 P.6.a.009 P.1.c.034 P.2.d.011 P.6.c.003 P.1.i.001 P.1.a.021 P.1.c.018 P.2.d.001 P.2.c.021 P.2.d.016 P.1.e.016 P.1.c.032 P.1.d.010 P.1.c.040 P.2.a.016 P.3.a.017 P.2.d.010 P.6.d.008 P.6.f.002 TravelECNP Award P.3.e.019 P.3.b.006 P.7.a.004 P.2.c.015 P.4.b.007 P.1.f.001 P.6.c.003 P.8.b.002 P.1.e.016 P.2.d.025 AwardPoster ECNP GeorgiaZhuravliova,Elene FranceSolinas,Marcello Dremencov,Eliyahu Israel ItalyDrago, Antonio ItalyFrancescaCalabrese, UnitedKingdom Bhattacharyya, Sagnik AwardFellowship ECNP FranceJacquesGlowinski, Award Achievement Lifetime ECNP Klaus-PeterGermany Lesch, Awardcology Neuropsychopharma­ ECNP 2008 Awardwinners 7 matters NebojsaZivkovic,Serbia Poland Zelek-Molik,Agnieszka VeronicaAustriaWitte, Kingdom TimUnitedWilliams, ElskeVrieze, Belgium Gerard NetherlandsThe, The Hungary Szabó, Zoltán Netherlands Schellekens, The Arnt SpainNoemíSantana, Netherlands Ruhe, G. HenricusThe IsraelRotberg, Benyamin SpainRamos-Miguel, Alfredo Pirovano,AdeleItaly UnitedKingdom Papadopoulos,Andreas Paggini,RosemmaItaly Nocon,Germany Agnes JelenaNesic,UnitedKingdom Spain Lopez, NegueruelaMonica HungaryEvaMikics, ItalyMazzola, Carmen ItalyGiovanniMartinotti, Pelfort,SpainLladó Laia Kusmider,Maciej Poland Jager, Gerry Netherlands The Jaako,KylliEstonia Germany Horstmann,Sonja Kingdom Haggerty,Daniel United Israel Golan,Moran Garnier,Carolina Spain Spain García-Gutiérrez,Salud María Kingdom Fornito,UnitedAlex TeresaSpainFemeníaCantó, Khoury,El Aram Sweden Netherlands Dumont, Glenn The ItalyDebbio, Del Alessandro Italy Carlino, Davide Italy Bossini, Letizia FranceNadiaBenturquia, Germany Behrendt,Silke SpainLopez-Garcia, Pilar PolandSzulc, Agata KoreaSouthJungwoo Son, Netherlands Ruhe, G. HenricusThe HungaryEvaMikics, JamesKesby, Australia Jager, Gerry Netherlands The Canada Gonzalez, Andrea Kingdom Fornito,UnitedAlex Dremencov,Eliyahu Israel interview 8 11 NeuropsychopharmacologyPsychiatryBiologicalfor Societyand Austrian societies national Meeting Calendar of ECNP Meetings ECNP of Calendar Information: www.agnp.deInformation: Germany München, 2009, October 10 - 7 26 NeuropsychopharmacologyPharmacopsychiatryof and Association German www.oegpb.atInformation: NovemberAustriaVienna,20 2009, - 19 e-mail: Scientific secretariat Scientific information: For further 2013 October 9 - 5 2012 October 17 - 13 3 - 7 September 2011 September 7 - 3 28 August - 1 September 2010 September 1 - August 28 phone: NetherlandsThe UtrechtAK 3508 P.O.85410 Box ECNP-Office fax: fax: 8567 253 30 +31 phone: NetherlandsThe UtrechtAK 3508 P.O.85410 Box ECNP-Office e-mail: information: For further PolandCzerniejewo, 2009, May 30 - 28 pharmacology NeuropsychoEPA- in - Seminar ECNP website: information: For further 2009, AprilTallinn, 25 - 23 Estonia 10 e-mail: website: information: For further FranceNice, 2010, March 9 - 7 • Topic: 8 Meeting Consultation ECNP Variabletopic FranceNice, 2010, March 7 - 4 Variabletopic FranceNice, 2009, March 8 - 5 • • • R YoungEurope for in cology Scientists WorkshopECNP Neuropsychopharma-on 2009 September 16 - 12 Congresses ECNP fax: e-mail: website: th th ecurrent topics: ecurrent Symposium Meeting Annual - chopharmacology neuropsy - in treatments new developing in medicine experimental and Biomarkers neuropsychopharmacology Clinical pharmacology Behavioural neuropsychopharmacologyMolecular 10 March 2009, Nice, FranceNice, 2009, March 10 th

+31 30 253 8568 253 30 +31 ECNP Regional Meeting Regional ECNP

[email protected] www.ecnp.eu +31 30 253 8567 253 30 +31 [email protected] [email protected] www.ecnp.eu +31 30 253 8568 253 30 +31 www.ecnp.eu [email protected] R R Bipolar disorders: towards new drug targets drug towardsnew disorders:Bipolar targets drug towardsnew Addiction: Organising secretariat 22 secretariat Organising 26 25 24 23 Belgium Brussels 1160 AvenueVanE. 6, Nieuwenhuyse ICEO) (formerly Brussels Colloquium 22 phone: phone: fax: e-mail: e-mail: th th th rd nd ECNP Congress, Amsterdam,Netherlands Congress, The ECNP ECNP Congress, Istanbul,Congress, TurkeyECNP ECNP Congress, Barcelona, SpainBarcelona,Congress, ECNP AustriaCongress,Vienna, ECNP Paris,Congress,France ECNP

+32 2 777 0188 777 2 +32 +32 2 779 5960 779 2 +32 [email protected] nd ECNP Congress ECNP IX XXIV [email protected] Information: Pennsylvania,Pittsburgh, JuneUSA 2009, 27 - 25 DisorderBipolar on ConferenceInternationalEighth www.comtecmed.com/copsyInformation: Germany,Berlin, June2009, 21 - 18 50 Neuro-Psychopharmacologyof College Scandinavian 8 www2.kenes.com/ebpf/pages/home.aspx Information: Belgium Brussels, 2009, February 26 - 25 2 Meetingsrelated organisations Information: www.ssbp.chInformation: SwitzerlandBern, 2009, March 26 - 25 Chronobiology and ResearchSleepMedicine, Sleep of SwissSociety the with meeting joint as Meeting Annual PsychiatryBiological of SwissSociety www.scnp.dkInformation: Denmark Copenhagen, 2009, April 29 - 27 Neuropsychopharmacology 9 www2.kenes.com/brain/pages/home.aspx Information: USA Chicago, July2009, 3 June- 29 1 www.update.europe.atInformation: AustriaJuneVienna,2009, 5 - 4 Information: forum.fens.org/2010 Information: Amsterdam,NetherlandsJuly 2010, The 7 - 3 7 www.aim-internationalgroup.comInformation: NovemberAustriaVienna,6 2009, - 4 15 www.nwg-goettingen.de/2009Information: Germany Göttingen, 2009, March 29 - 25 JulienBelgium Mendlewicz, Klaus-PeterGermany Lesch, Josifovic-Kostic,Dragana Serbia Estonia JaanusHarro, FranceJacquesGlowinski, ItalyFilippoDrago, Brazil Carobrez, Antonio NetherlandsBohn, MariaThe Ligia Contributors Ree,Netherlands van The JanM. Committee Publication Chair FranceHamon, Michel ProgrammeFutureScientific Committee Chair SwedenÖgren,Sven Ove ProgrammeScientific Committee Chair SpainEduardVieta, Rihmer,Zoltán Hungary FranceMillan,Mark UnitedKingdom Laruelle, Marc Holsboer-Trachsler,Edith Switzerland UnitedKingdom Goodwin, Guy ItalyBrunello,Nicoletta Spain Arango, Celso Councillors: France,Hamon, Michel Germany,Hans-UlrichWittchen, JulienBelgium, Mendlewicz, JosephZohar, Israel, Netherlands,Kahn, The S. René David ExecutiveCommittee JosephZohar, Israel Nutt,UnitedKingdom, David Committee Editorial Ree,Netherlands, van The JanM. adviser Netherlands, The Koole-Krusemeijer, K. Jocelyn MariaVrijmoed-de Vries, Netherlands, The by Edited Neuropsychopharmacology(ECNP). of College European the of publication a is Matters ECNP ecnp th th st th nd WorldPsychiatry in Controversies on Congress th FENS Forum of EuropeanNeuroscienceof Forum FENS DisordersAnxiety and Mood on ForumInternational th th European Brain Policy Forum: a focus on depression and the Europeansociety the and depression on EuropeanBrainfocus Policy a Forum: Göttingen Meeting of the German NeuroscienceGermanSociety the of Meeting Göttingen International Conference on Quantification of Brain Function with PETBrainFunctionwith of Quantification on ConferenceInternational Update in Psychiatry Updatein Annual Meeting as a joint meeting with the Canadian College of College Canadian the with meeting joint a as Meeting Annual th Nutt,UnitedKingdom, nentoa Smoim n eerl lo Fo, eaoim n Fnto & Function and Metabolism Flow, Blood Cerebral on Symposium International president-elect matters treasurer

past-president president chair vice-president

secretary adviser editor ecnp away of ECNP members. ECNP of away passing the on news have you if [email protected] at ECNP-Office the inform Please cited. is publication of place original the and addition or omission by distorted information not is sense the as long as newsletter any this in found of text the reproduce to is given Permission copy. the in changes major about to consulted are writers right copy.The shorten or the refuse have does The however, article. staff, the editorial of writer named the of sibility respon- the are staff.They editorial the or ECNP of those necessarily not are views expressed The ECNP Matters is carefully prepared and published. by held otherwise. stated specifically unless ECNP is material published all for Copyright email: fax: phone: NetherlandsThe UtrechtAK 3508 85410 Box PO ECNP-Office to: sent be can maximum) words (600 Copy 2009 April 15 issue: next Deadline copy for Call NetherlandsThe Teewes TextpresseBedrijvenGrafische Printing Edelenbos,Netherlands Elsa The WebDesign NetherlandsThe Direction Art and Design HoogeveenPieter DesignGraphic AustraliaWilson,Craig MariaVrijmoed-de Vries, Netherlands The SpainEduardVieta, Sergio TomaselliItalyMarzano, WalterPirker, Austria SwedenÖgren,Sven Ove [email protected] 8568 253 30 +31 8567 253 30 +31 matters